Pharmaceutical Industry 16 – 22 March: Featuring MHRA, Aplagon and UCB
- MHRA has approved deuruxolitinib, marketed as Leqselvi, for adults with severe alopecia areata, adding a new prescription treatment option for the autoimmune condition.
- Aplagon has dosed the first patient in its phase 2a HEALING trial of APAC for peripheral arterial occlusive disease and chronic limb threatening ischaemia in Finland.
- UCB has reported positive topline results from its BE BOLD trial, with bimekizumab showing superiority over risankizumab in active psoriatic arthritis at Week 16.
The pharmaceutical industry has seen another wave of meaningful progress, with fresh developments spanning regulatory approval, early-to-mid-stage clinical advancement and competitive trial performance.
In one update, the UK’s Medicines and Healthcare products Regulatory Agency has approved a new treatment for severe alopecia areata in adults. In another, Finnish biotechnology company Aplagon has moved a first-in-class vascular therapy into a phase 2a patient study.
Meanwhile, UCB has posted positive topline data from what it describes as a landmark head-to-head psoriatic arthritis trial.
Taken together, these announcements reflect more than routine momentum. They show an industry continuing to push forward on three fronts at once: bringing new medicines to market, expanding the clinical evidence base for novel platforms, and sharpening the competitive profile of established biologic strategies.
For patients and clinicians alike, that matters.
MHRA Approval of Leqselvi Opens a New Option in Alopecia Areata
The MHRA’s approval of deuruxolitinib, marketed as Leqselvi, marks a notable step forward for adults living with severe alopecia areata, an autoimmune condition in which the immune system attacks hair follicles and causes hair loss affecting the scalp, face or other parts of the body.
For many people, alopecia areata is not simply a cosmetic concern. It can carry a substantial psychological and emotional burden, particularly in severe cases where hair loss is extensive and persistent.
The approval of a new medicine in this space therefore carries weight beyond the clinical headline.
Leqselvi works by reducing the activity of JAK1, JAK2 and TYK2 relative to JAK3 kinases, enzymes involved in the inflammatory process at the hair follicle. By dampening that inflammation, the medicine can help support hair regrowth. It is available only on prescription, with a recommended dose of 8 mg taken twice daily.
The approval was supported by two pivotal clinical trials involving 1,223 adults who had lost at least 50 percent of their hair for more than six months. Participants received either Leqselvi 8 mg, deuruxolitinib 12 mg or a placebo, taken twice daily over 24 weeks.
The results showed that those treated with Leqselvi achieved higher scores on a standard measure of scalp hair coverage than those given placebo.
After 24 weeks, around 30 percent of subjects experienced 80 percent or more scalp hair, while around 23 percent achieved 90 percent or more. Those figures suggest clinically meaningful regrowth in a patient group with substantial unmet need.
The MHRA has made clear that, as with any medicine, the safety and effectiveness of deuruxolitinib will remain under close review.
That balance between access and vigilance is central to modern medicines regulation, and it is especially important as targeted therapies continue to expand into specialised immune-mediated conditions.
Aplagon Pushes APAC Into Phase 2a With First Patient Dosed
While Leqselvi represents a regulatory milestone, Aplagon’s latest announcement shows the next stage of innovation in motion.
The company has dosed the first patient in its phase 2a HEALING clinical trial of APAC, a first-in-class treatment being evaluated for thrombo-inflammatory diseases in patients with peripheral arterial occlusive disease and chronic limb threatening ischaemia.
The study is being conducted in Finland and is expected to enrol up to 42 patients across four cohorts. It will assess the safety and preliminary efficacy of APAC delivered intravenously, while also examining its impact on thrombo-inflammatory biomarkers in patients with and without revascularisation.
This is an area of medicine where the clinical need is serious and immediate. Chronic limb threatening ischaemia, a severe form of PAOD caused by atherosclerosis-related thrombo-inflammation, leads to critically reduced blood flow and carries a high risk of amputation.
Its one-year mortality rate of 25 percent underlines just how severe the condition can be.
Aplagon’s progress into phase 2a follows a successful international phase 1 study in 30 healthy volunteers, where APAC was reported to be well tolerated and demonstrated dose-dependent, transient systemic antithrombotic effects.
A related PET-imaging study using 89zirconium-labelled APAC is also expected to complete in the first half of 2026, potentially adding another layer of insight into how the therapy behaves in the body.
The company’s proposition is particularly interesting because APAC is based on a heparin proteoglycan mimetic with the ability to target and remain at sites of vascular injury. That gives it a broader platform feel, rather than the profile of a one-indication asset.
The treatment’s flexibility in being administered locally or intravenously in a hospital setting may also support its adoption by vascular surgeons and angiologists if the data continue to develop positively.
Importantly, the clinical rationale appears to extend beyond clot prevention alone. According to the study’s vascular surgery leadership, APAC has shown the ability to prevent platelet aggregation and blood clotting, while previous work also suggests it may reduce inflammatory responses in oxygen-deprived tissues.
The hope is that this dual-action approach could improve treatment of lower limb arterial atherosclerosis, accelerate the healing of ischaemic tissue damage and help prevent restenosis after revascularisation, ultimately reducing the need for repeat interventions.
Aplagon is already looking ahead, with plans for a phase 2 trial in 2026 in arteriovenous fistula maturation failure in Europe, following encouraging phase 1 findings. That tells its own story: a company that sees its platform as having multiple shots on goal.
UCB’s BE BOLD Results Add Competitive Edge in Psoriatic Arthritis
At the commercial and clinical interface, UCB has delivered one of the more eye-catching datasets of the moment. The company announced positive topline results from BE BOLD, a phase 2 head-to-head study in adults with active psoriatic arthritis, comparing bimekizumab with risankizumab.
According to UCB, bimekizumab achieved statistically significant superiority in the ACR50 primary efficacy endpoint at Week 16, making this the first head-to-head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL-23 inhibitor.
That point matters because head-to-head data carry particular weight in treatment decision-making. In crowded immunology markets, superiority claims are hard won and commercially significant.
They also provide physicians with more direct comparative evidence than placebo-controlled trials alone.
Bimekizumab is already notable as the first approved medicine to selectively inhibit both interleukin 17A and interleukin 17F. UCB says treatment in the trial was generally well tolerated, with no new safety signals seen during the 16-week study period.
The company has framed BE BOLD as a landmark study, and it is not difficult to see why. UCB says this is now the fourth head-to-head study showing superiority for bimekizumab, further strengthening the product’s position across immune-mediated inflammatory diseases.
Full results are due to be submitted to an upcoming international congress, where the details will be closely watched by clinicians, competitors and investors alike.
What This Means for Pharmaceutical Manufacturing and Production
These developments also carry broader implications for pharmaceutical manufacturing and pharmaceutical production.
The approval of Leqselvi adds fresh demand for a targeted oral therapy in an autoimmune indication, requiring reliable tablet production, quality control and prescription supply planning.
Aplagon’s APAC programme, still in clinical development, points to the manufacturing demands that come with first-in-class vascular medicines, especially where specialised formulation, hospital delivery and scalable clinical supply are concerned.
UCB’s bimekizumab results, meanwhile, reinforce the importance of biologics manufacturing capacity, consistency and long-term production planning in a market where stronger comparative data can rapidly influence demand.
In short, the news is a reminder that success in modern pharma is not just about discovery or trial data. It also depends on whether manufacturing systems are robust enough to support approval, adoption and growth.
Conclusion
From the MHRA’s approval of Leqselvi for severe alopecia areata, to Aplagon’s first patient dosed in the HEALING trial, to UCB’s strong BE BOLD topline results, this is a set of updates that captures the pharmaceutical industry in active motion.
Different diseases, different technologies and different stages of development, but one clear common thread: the push to deliver better options for patients through sharper science and stronger evidence.
For the sector, that is the bigger picture. New approvals expand treatment choice. Mid-stage trials keep the pipeline moving. Head-to-head victories help redefine standards of care. And behind all of it sits an industry still doing what it is ultimately expected to do at its best – turn scientific promise into practical therapeutic progress.
News Credits:
MHRA approves new treatment for severe alopecia areata
Aplagon doses first patient in phase 2a trial of APAC
UCB reports superiority of bimekizumab in psoriatic arthritis study
Vous aimerez peut-être aussi :